Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors.

Trial Profile

Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2010

At a glance

  • Drugs Docetaxel; Lenalidomide
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Mar 2010 Actual initiation date changed from Jun 2004 to Jun 2005 and actual patient number (33) as reported by ClinicalTrials.gov.
    • 02 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2007 Status change from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top